KPTI (Karyopharm Therapeutics) Valuation Rank


KPTI Karyopharm Therapeutics Inc KPTI
52 GF Score
Price $9.60
GF Value $6.37
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Karyopharm Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Karyopharm Therapeutics Valuation Rank Related Terms

KPTI
52GF Score
Karyopharm Therapeutics Inc KPTI
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?

Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued. The current stock price of $9.60 is trading 50.7% above its estimated GF Value™ of $6.37. GuruFocus considers Karyopharm Therapeutics to be Significantly Overvalued.

Key valuation signals for KPTI:

  • Valuation Rank:
  • GF Value™: $6.37 vs. price of $9.60 (50.7% above fair value)
  • GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Karyopharm Therapeutics Business Description

Other Exchanges 25K0:Germany
Address 85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
52GF Score

Get the complete analysis for KPTI

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.60
Price
$6.37
GF Value